Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2020.
- 04 May 2016 Status changed from active, no longer recruiting to recruiting.
- 08 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.